Wikidata

(Q105493454)

English

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

clinical trial

In more languages

Statements

short name
INTERLINK-1 (English)
0 references
title
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor (English)
0 references
sponsor
AstraZeneca
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Bulgaria
0 references
Canada
0 references
France
0 references
Germany
0 references
Greece
0 references
Italy
0 references
Japan
0 references
Netherlands
0 references
Peru
0 references
Philippines
0 references
Poland
0 references
Portugal
0 references
Romania
0 references
Spain
0 references
Switzerland
0 references
Taiwan
0 references
United Kingdom
0 references
start time
2 October 2020
0 references
end time
28 March 2024
0 references
number of participants
600
0 references
minimum age
18 year
0 references
maximum age
130 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q105493454&oldid=2148642591"